Comparative Efficacy Analysis of Mobilization and Collection of Autologous Hematopoietic Stem Cells in Patients with Lymphoproliferative Disorders and Multiple Sclerosis

BONE MARROW TRANSPLANTATION , , , ,

OV Fedyk, VO Sarzhevskii, DA Fedorenko, VYa Mel’nichenko, YuN Dubinina, NE Mochkin, EG Smirnova, DS Kolesnikova, AE Bannikova

NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203

For correspondence: Oksana Vladimirovna Fedyk, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203; Tel.: +7(968)748-93-42; e-mail: ksen1005@inbox.ru.

For citation: Fedyk OV, Sarzhevskii VO, Fedorenko DA, et al. Comparative Efficacy Analysis of Mobilization and Collection of Autologous Hematopoietic Stem Cells in Patients with Lymphoproliferative Disorders and Multiple Sclerosis. Clinical oncohematology. 2019;12(1):51–8.

DOI: 10.21320/2500-2139-2019-12-1-51-58

ABSTRACT

Aim. Comparative efficacy analysis of autologous hematopoietic stem cells (HSC) prior to auto-HSCT in patients with lymphoproliferative disorders (LPDs) and multiple sclerosis (MS).

Materials & Methods. The trial included 237 patients: 103 LPD and 134 MS patients. In 225 patients HSC mobilization involved only colony-stimulating factors (CSFs), in 12 patients chemotherapy (cyclophosphamide, etoposide) was combined with CSFs. On the intended date of cytapheresis all the patients were tested for CD34+ marker expression. Сytapheresis followed in the patients with CD34+ count more than 0.01 × 106/mL.

Results. In 23 (22 %) LPD patients CD34+ count was too low for auto-HSCT (‘collection failure group’). Within this group 19 patients received CSF mobilization, and 4 patients received chemotherapy + CSF. Plerixafor was administered in 5 patients, in 4 of them a repeated mobilization also failed to collect enough cells. In 80 LPD patients the number of mobilized and collected CD34+ cells was sufficient for auto-HSCT (‘collection success group’). Within this group 77 patients received auto-HSCT, 74 patients were treated with CSF mobilization, 6 patients received chemotherapy + CSF, and in 11 patients plerixafor was administered. Median total number of CD34+ cells in the ‘collection success group’ was 2.7 × 106/kg. All 134 MS patients had enough CD34+ cells for auto-HSCT. All of them received CSF mobilization. Median total number of CD34+ cells in the MS group was 2.34 × 106/kg. Potential risk factors for HSC mobilization failure in LPDs were evaluated. They included age, gender, prior radiotherapy, number of antitumor treatment lines prior to auto-HSCT, clinical response prior to auto-HSCT (complete/partial remission or stabilization), and HSC mobilization regimen. These factors with the exception of gender were not associated with mobilization failure parameters. The worst mobilization outcomes were reported in male patients.

Conclusion. In 22 % of LPD patients the planned high-dose chemotherapy and auto-HSCT failed due to insufficient counts of autologous CD34+ cells in apheresis product. Male gender can be considered to be a prognostic factor of mobilization failure in LPDs.

Keywords: lymphoproliferative disorders, autologous transplantation, mobilization of peripheral blood stem cells, autoimmune diseases, multiple sclerosis.

Received: June 25, 2018

Accepted: December 8, 2018

Read in PDF 

REFERENCES

  1. Giralt S, Costa L, Schriber J, et al. Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308. doi: 10.1016/j.bbmt.2013.10.013.

  2. Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant. 2011;17(1):20–47. doi: 10.1016/j.bbmt.2010.07.008.

  3. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677–84. doi: 10.1182/blood-2004-10-3883.

  4. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–4. doi: 10.1016/0140-6736(93)92411-l.

  5. Mounier N, Canals C, Gisselbrecht C, et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant. 2012;18(5):788–93. doi: 10.1016/j.bbmt.2011.10.010.

  6. Hermine О, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–75. doi: 10.1016/S0140-6736(16)00739-X.

  7. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5. doi: 10.1056/NEJM199512073332305.

  8. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71. doi: 10.1016/S0140-6736(02)08938-9.

  9. Atkins H. Hematopoietic SCT for the treatment of multiple sclerosis. Bone Marrow Transplant. 2010;45(12):1671–81. doi: 10.1038/bmt.2010.168.

  10. Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015;72(2):159–69. doi: 10.1001/jamaneurol.2014.3780.

  11. Shevchenko J, Kuznetcov A, Ionova T, et al. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives. Ann Hematol. 2015;94(7):1149–57. doi: 10.1007/s00277-015-2337-8.

  12. Федоренко Д.А. Принципы оценки эффективности аутологичной трансплантации гемопоэтических стволовых клеток у больных лимфомами и рассеянным склерозом: Дис. … д-ра мед. наук. М., 2015. 188 с.

    [Fedorenko DA. Printsipy otsenki effektivnosti autologichnoi transplantatsii gemopoeticheskikh stvolovykh kletok u bol’nykh limfomami i rasseyannym sklerozom. (Principles of efficacy estimation of autologous hematopoietic stem cell transplantation in lymphoma and multiple sclerosis patients.) [dissertation] Moscow; 2015. (In Russ)]

  13. Покровская О.С. Механизм действия и клиническая эффективность антагониста хемокинового рецептора CXCR4 плериксафора при мобилизации гемопоэтических стволовых клеток. Клиническая онкогематология. 2012;5(4):371–9.

    [Pokrovskaya OS. Mechanism of action and clinical activity of CXCR4 antagonist Plerixafor in stem cell mobilization. Klinicheskaya onkogematologiya. 2012;5(4):371–9. (In Russ)]

  14. Покровская О.С. Системные эффекты Г-КСФ при мобилизации стволовых клеток крови (СКК) у больных множественной миеломой (ММ). Клиническая онкогематология. 2009;2(1):67–8.

    [Pokrovskaya OS. Systemic effects of G-CSF in peripheral stem cells (PSC) mobilization in multiple myeloma (MM) patients. Klinicheskaya onkogematologiya. 2009;2(1):67–8. (In Russ)]

  15. Lemoli RM. New Strategies for Stem Cell Mobilization. Mediterr J Hematol Infect Dis. 2012;4(1):e2012066. doi: 10.4084/MJHID.2012.066.

  16. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37(8):719–24. doi: 10.1038/sj.bmt.1705298.

  17. Kim JG, Sohn SK, Chae YS, et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2007;40(10):919–24. doi: 10.1038/sj.bmt.1705841.

  18. Blank N, Lisenko K, Pavel P, et al. Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease. Eur J Haematol. 2016;97(1):78–82. doi: 10.1111/ejh.12686.

  19. Kyrcz-Krzemien S, Helbig G, Torba K, et al. Safety and efficacy of hematopoietic stem cells mobilization in patients with multiple sclerosis. Hematology. 2016;21(1):42–5. doi: 10.1080/10245332.2015.1101973.

  20. Моталкина М.С., Кулева С.А., Алексеев С.М. и др. Пример успешной мобилизации стволовых кроветворных клеток периферической крови с помощью плериксафора и пэгфилграстима у пациентки с неходжкинской лимфомой. Современная онкология. 2015;17(2):54–6.

    [Motalkina MS, Kuleva SA, Alekseev SM, et al. An example of successful mobilization of peripheral blood stem cells from with plerixafor and pegfilgrastim administration in a non-Hodgkin’s lymphoma patient. Sovremennaya onkologiya. 2015;17(2):54–6. (In Russ)]

  21. Wuchter P, Ran D, Bruckner T, et al. Poor Mobilization of Hematopoietic Stem Cells-Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation. Biol Blood Marrow Transplant. 2010;16(4):490–9. doi: 10.1016/j.bbmt.2009.11.012.

  22. Mendrone AJr, Arrais CA, Saboya R, et al. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci. 2008;39(3):187–92. doi: 10.1016/j.transci.2008.09.012.

  23. To LB, Levesque J-P, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118(17):4530–40. doi: 10.1182/blood-2011-06-318220.